EPO Patent EP4630041A1 for Kit Treating Hematological Cancer
Summary
The European Patent Office has published patent application EP4630041A1 for a kit used in the treatment of hematological cancer. The patent is assigned to AvenCell Europe GmbH and was published on March 18, 2026.
What changed
The European Patent Office (EPO) has published patent application EP4630041A1, detailing a kit for treating hematological cancer. The application was filed by AvenCell Europe GmbH and includes specific International Patent Classification (IPC) codes related to pharmaceutical preparations. This publication is an announcement of a granted patent, not a regulatory rule or guidance.
This patent publication does not impose new regulatory obligations on pharmaceutical companies or healthcare providers. It signifies intellectual property protection for AvenCell Europe GmbH's technology. Compliance officers in the pharmaceutical sector should note this patent as it relates to a specific therapeutic area and may impact future market exclusivity or licensing agreements for similar treatments.
Source document (simplified)
A KIT FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCER
Publication EP4630041A1 Kind: A1 Mar 18, 2026
Applicants
AvenCell Europe GmbH
Inventors
EHNINGER, Gerhard, CARTELLIERI, Marc, EHNINGER, Armin
IPC Classifications
A61K 39/00 20060101AFI20240614BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.